Biomarkers in Oncology | Access and Reimbursement | US | 2017
Biomarker-targeted therapies are distinguished from other oncology drugs in that they are accompanied by a diagnostic test that can identify a specific patient type most likely to benefit from therapy. This form of personalized medicine is well entrenched in the treatment of non-small-cell lung cancer and malignant melanoma, and is playing an increasingly important role in the management of patients with BRCA-mutant ovarian cancer. While biomarker-targeted therapies offer the advantage of selecting the patients most likely to respond to treatment, these therapies are premium priced and are often subject to payer restrictions. DRG explores the drivers and barriers associated with use of these agents and reports on how reimbursement impacts drug selection and prescribing. We also evaluate surveyed physicians’ and surveyed payers’ perceptions of emerging biomarker-targeted-therapies.
QUESTIONS ANSWERED
- What factors most greatly influence payers’ reimbursement decisions for biomarker-driven therapies in NSCLC, malignant melanoma, and ovarian cancer? What restrictions do they impose?
- Do access and reimbursement challenges differ by indication and/or how well established the biomarker is in each indication?
- What roles do reimbursement, cost, and clinical factors play in oncologists’ decisions to prescribe biomarker-driven therapies?
- What are payer opinions of emerging agents, and how will oncologists’ prescribing patterns change with the launch of new therapies?
- What factors influence reimbursement and access of companion biomarker tests?
PRODUCT DESCRIPTION
Access & Reimbursement:
Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.
